65,437 trials
COVID-19
Primary: Safety/Tolerability Assessed by Rates of Grade 3 or 4 Post Randomization Adverse Events — 1; 1 Participants
SARS-CoV-2 Infection, COVID-19
Primary: Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs — 21; 48; 49; 49 Participants — p=0.5551
Chronic Spontaneous Urticaria
Primary: Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 — -19.10; -19.08; -14.65; -15.99 Scores on a scale — p=<0.0001
Schizophrenia · Schizo Affective Disorder
Primary: Mean Auditory Hallucination Rating Scale (AHRS) Score — 25.00; 23.17; 23.40; 19.00 score on a scale — p=0.66
Sleep Apnea, Obstructive · Heart Failure
Primary: All-cause Hospital Readmission Within 30 Days of Hospital Discharge. — 3 readmissions
Bleeding
Primary: Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor — -93.3; -94.1; -71.3; -75.41 Percent Change
Mitral Valve Regurgitation · Mitral Regurgitation
Primary: Safety Measure: Number of Participants With Major Adverse Events (MAE) — 24; 0; 8; 11 Participants
Postoperative Atelectasis
Primary: Partial Pressure of Oxygen (PaO2 Level) — 95.4; 83.5; 92.1; 85.4 mmHg
Ebola
Primary: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase — 0.85; 0.76 proportion of semen samples
Eosinophilia · Hypereosinophilic Syndrome · Leukocyte Disorder
Primary: Mean Percent Change in Eosinophil Count After Glucocorticoid Challenge — -69.6; -13.6 percentage of eosinophil count
Cognitive Disorders · Delirium · Acute Kidney Injury
Primary: Number of Patients With Postoperative Cognitive Dysfunction — 16; 10 Participants — p=0.23
Multiple Sclerosis (MS)
Primary: Annualized Relapse Rate (ARR) From the Time of Cessation of Natalizumab Treatment. — 0 number of relapses in a year
Alzheimer Disease
Primary: Change From Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score — -6.86; -10.06 score on a scale — p=0.042
COVID-19
Primary: Ventilator Free Survival — 58; 19; 44 Participants
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Intraocular Pressure — 20.35; 20.79; 17.38; 18.31 mmHg — p=0.0006